This growth was, to a large degree, driven by the generics market that showed an impressive growth rate of 14 per cent by value over the last decade (CAGR 2001-2009) reaching a size of almost 90 ...
The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...
Biosimilars are to biologic drugs what generics are to pharmaceuticals - they enter the market after the original biologic drug's patent expires, offering a highly similar product with equivalent ...
After offloading a big chunk of their Japanese generics joint venture in 2020, Teva and Takeda have decided to divest the business in its entirety so they can each focus on their innovative medicines.